Target General Information
Target ID T71377 Target Info
Target Name Interleukin 3 receptor alpha (IL3RA)
Synonyms Interleukin-3 receptor subunit alpha; IL3R; IL-3RA; IL-3R-alpha; IL-3R subunit alpha; IL-3 receptor subunit alpha; CD123 antigen; CD123
Target Type Successful Target
Gene Name IL3RA
Biochemical Class Cytokine receptor
UniProt ID
Targeted Antigens of CAR-T Cell Therapy
CAR T-Cell Therapy Drug(s) CD123/CLL1 CAR-T Cells Drug Info Phase 2/3 Acute myeloid leukaemia [1]
4SCAR19 and 4SCAR123 Drug Info Phase 1/2 B-cell lymphoma [2]
Anti-CD123-CAR-transduced T cells Drug Info Phase 1/2 leukaemia [3]
CART-123 cells Drug Info Phase 1/2 Acute myeloid leukaemia [4]
CD123-specific gene-engineered T cells Drug Info Phase 1/2 Acute myeloid leukaemia [5]
Anti-CD123 CAR-T cells Drug Info Phase 1 Lymphoma [6]
CART-123 cells Drug Info Phase 1 Myelodysplastic syndrome [7]
CART123 cells Drug Info Phase 1 Acute myeloid leukaemia [8]
CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells Drug Info Phase 1 Acute myeloid leukaemia [9]
IM23 Drug Info Phase 1 Acute myeloid leukaemia [10]
UCART123 Drug Info Phase 1 Blastic plasmacytoid dendritic cell neoplasm [11], [12]
Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes Drug Info Phase 0 Acute myeloid leukaemia [13]
CAR-T cells targeting CD123 Drug Info Preclinical Acute myeloid leukaemia [14]
References
REF 1 ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
REF 2 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
REF 3 ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
REF 4 ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
REF 5 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
REF 6 ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
REF 7 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
REF 8 ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML
REF 9 ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
REF 10 ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
REF 11 ClinicalTrials.gov (NCT03203369) Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
REF 12 ClinicalTrials.gov (NCT03190278) Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia
REF 13 ClinicalTrials.gov (NCT02623582) CD123 Redirected Autologous T Cells for AML
REF 14 ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.